TransMedics Group, Inc. (TMDX) Stock
Healthcare · Medical Devices · Member of Other US Stocks
TransMedics Group, Inc. (TMDX) closed at USD 76.52 on 2026-10-15, a change of -43 % over the past year, with a market capitalization of USD 2.45B.
TransMedics Group, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-15 | 76.52 |
| 2026-10-14 | 75.52 |
| 2026-10-13 | 79.14 |
| 2026-10-12 | 78.17 |
| 2026-10-09 | 77.87 |
| 2026-10-08 | 79.00 |
| 2026-10-07 | 81.07 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
TransMedics Group, Inc. key figures
- Previous close
- USD 76.52 (2026-10-15)
- 1-year change
- -43 %
- Market cap
- USD 2.45B
- Enterprise value
- USD 2.85B
- P/E ratio (trailing)
- 18.34
- P/E ratio (forward)
- 31.40
- EPS (trailing)
- 3.86
- EPS (forward)
- 2.25
- PEG ratio
- 0.66
- Price to book
- 4.73
- Revenue growth
- 20.7 %
- Earnings growth
- -55.8 %
- Dividend per share (trailing)
- 0.00
- Short ratio
- 11.71
- Employees
- 898
- Analyst consensus (third-party)
- buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for TransMedics Group, Inc. and compare it with other stocks.
Analyze TMDXAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell TransMedics Group, Inc. shares.